{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:52:50Z","timestamp":1793141570074,"version":"4.5.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.semarthrit.2026.153040","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T23:29:14Z","timestamp":1783380554000},"page":"153040","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Efficacy and safety of Janus kinase inhibitors in Beh\u00e7et\u2019s disease: A systematic literature review"],"prefix":"10.1016","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9648-1130","authenticated-orcid":false,"given":"Fadi","family":"Hassan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmud","family":"Omar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helana","family":"Jeries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6653-1758","authenticated-orcid":false,"given":"Fatma","family":"Alibaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9777-2864","authenticated-orcid":false,"given":"Mohammad E.","family":"Naffaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.semarthrit.2026.153040_bib0001","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s10238-004-0045-0","article-title":"Behcet\u2019s disease","volume":"4","author":"Al-Mutawa","year":"2004","journal-title":"Clin Exp Med"},{"issue":"8","key":"10.1016\/j.semarthrit.2026.153040_bib0002","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/j.1365-4632.2006.02832.x","article-title":"Vascular involvement in Beh\u00e7et's disease: a retrospective analysis of 2319 cases","volume":"45","author":"Sarica-Kucukoglu","year":"2006","journal-title":"Int J Dermatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2026.153040_bib0003","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.revmed.2013.12.002","article-title":"Atteintes cardiovasculaires de la maladie de Beh\u00e7et [Cardiovascular involvement in Beh\u00e7et's disease]","volume":"35","author":"Desbois","year":"2014","journal-title":"Rev Med Interne"},{"issue":"7","key":"10.1016\/j.semarthrit.2026.153040_bib0004","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11910-018-0843-5","article-title":"Beh\u00e7et's syndrome and nervous system involvement","volume":"18","author":"Uyguno\u011flu","year":"2018","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"4","key":"10.1016\/j.semarthrit.2026.153040_bib0005","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00415-009-0145-6","article-title":"The spectrum of nervous system involvement in Beh\u00e7et's syndrome and its differential diagnosis","volume":"256","author":"Siva","year":"2009","journal-title":"J Neurol"},{"issue":"10","key":"10.1016\/j.semarthrit.2026.153040_bib0006","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1093\/rheumatology\/keaa010","article-title":"Epidemiology, morbidity and mortality in Beh\u00e7et's disease: a cohort study using the health improvement network (THIN)","volume":"59","author":"Thomas","year":"2020","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.semarthrit.2026.153040_bib0007","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/00005792-200301000-00006","article-title":"The long-term mortality and morbidity of Beh\u00e7et syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center","volume":"82","author":"Kural-Seyahi","year":"2003","journal-title":"Medicine"},{"key":"10.1016\/j.semarthrit.2026.153040_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2024.110239","article-title":"The safety and efficacy of TNF inhibitors in patients with Beh\u00e7et's disease: retrospective study from eastern Turkey","volume":"264","author":"Bekta\u015f","year":"2024","journal-title":"Clin Immunol"},{"key":"10.1016\/j.semarthrit.2026.153040_bib0009","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jaut.2015.06.005","article-title":"Efficacy of anti-TNF alpha in severe and\/or refractory Beh\u00e7et's disease: multicenter study of 124 patients","volume":"62","author":"Vallet","year":"2015","journal-title":"J Autoimmun"},{"issue":"2","key":"10.1016\/j.semarthrit.2026.153040_bib0010","doi-asserted-by":"crossref","first-page":"keag021","DOI":"10.1093\/rheumatology\/keag021","article-title":"Tumor necrosis factor alpha inhibitors in Beh\u00e7et's disease: indications, efficacy, and safety of two widely used agents","volume":"65","author":"Deniz","year":"2026","journal-title":"Rheumatology"},{"issue":"3","key":"10.1016\/j.semarthrit.2026.153040_bib0011","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/jgh.16056","article-title":"Long-term clinical outcomes of intestinal Beh\u00e7et's disease: a 30-year cohort study at a tertiary hospital in South Korea","volume":"38","author":"Park","year":"2023","journal-title":"J Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2026.153040_bib0012","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1093\/mr\/roab127","article-title":"Predictors of infliximab refractory intestinal Beh\u00e7et's syndrome: a retrospective cohort study from the Shanghai Beh\u00e7et's syndrome database","volume":"33","author":"Bao","year":"2023","journal-title":"Mod Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2026.153040_bib0013","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3349\/ymj.2022.0264","article-title":"Risk factors for surgery in patients with intestinal beh\u00e7et's disease during anti-tumor necrosis factor-alpha therapy","volume":"64","author":"Han","year":"2023","journal-title":"Yonsei Med J"},{"issue":"10431","key":"10.1016\/j.semarthrit.2026.153040_bib0014","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S0140-6736(23)02629-6","article-title":"Beh\u00e7et's syndrome","volume":"403","author":"Emmi","year":"2024","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.semarthrit.2026.153040_bib0015","article-title":"Activation of the JAK\/STAT pathway in Behcet's disease","volume":"16","author":"Tulunay","year":"2015","journal-title":"Genes Immun"},{"issue":"4","key":"10.1016\/j.semarthrit.2026.153040_bib0016","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3390\/pathogens14040324","article-title":"The dual-edged sword: risks and benefits of JAK inhibitors in infections","volume":"14","author":"Jarneborn","year":"2025","journal-title":"Pathogens"},{"key":"10.1016\/j.semarthrit.2026.153040_bib0017","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.semarthrit.2026.153040_bib0018","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1080\/02763869.2019.1588072","article-title":"PROSPERO: an international register of systematic review protocols","volume":"38","author":"Schiavo","year":"2019","journal-title":"Med Ref Serv Q"},{"issue":"10","key":"10.1016\/j.semarthrit.2026.153040_bib0019","first-page":"2127","article-title":"Methodological quality of case series studies: an introduction to the JBI critical appraisal tool","volume":"18","author":"Munn","year":"2020","journal-title":"JBI Evid Synth"},{"issue":"11","key":"10.1016\/j.semarthrit.2026.153040_bib0020","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1136\/annrheumdis-2020-217307","article-title":"A pilot study of tofacitinib for refractory Beh\u00e7et's syndrome","volume":"79","author":"Liu","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2026.153040_bib0021","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X221124014","article-title":"Tofacitinib as an alternative therapy for refractory intestinal Beh\u00e7et's syndrome","volume":"14","author":"Zou","year":"2022","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.semarthrit.2026.153040_bib0022","article-title":"Case report: refractory intestinal Beh\u00e7et's syndrome successfully treated with tofacitinib: a report of four cases","volume":"13","author":"Zhao","year":"2022","journal-title":"Front Immunol"},{"issue":"15","key":"10.1016\/j.semarthrit.2026.153040_bib0023","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000029189","article-title":"Extended-release tofacitinib for refractory Beh\u00e7et disease: a case report","volume":"101","author":"Wang","year":"2022","journal-title":"Medicine"},{"issue":"4","key":"10.1016\/j.semarthrit.2026.153040_bib0024","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/jgh.15997","article-title":"Refractory parastomal ulcers of Behcet's disease responsive to tofacitinib","volume":"38","author":"Lin","year":"2023","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.semarthrit.2026.153040_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2023.109241","article-title":"Baricitinib for the treatment of intestinal Beh\u00e7et's disease: a pilot study","volume":"247","author":"Liu","year":"2023","journal-title":"Clin Immunol"},{"key":"10.1016\/j.semarthrit.2026.153040_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2023.109298","article-title":"Baricitinib for the treatment of refractory vascular Beh\u00e7et's disease","volume":"250","author":"Wang","year":"2023","journal-title":"Clin Immunol"},{"issue":"7","key":"10.1016\/j.semarthrit.2026.153040_bib0027","doi-asserted-by":"crossref","DOI":"10.1111\/1756-185X.15275","article-title":"Case report: Peristomal pyoderma gangrenosum complicated by rheumatoid arthritis and Beh\u00e7et's disease successfully treated with baricitinib","volume":"27","author":"Ito","year":"2024","journal-title":"Int J Rheum Dis"},{"issue":"8","key":"10.1016\/j.semarthrit.2026.153040_bib0028","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1080\/09273948.2023.2263557","article-title":"Successful remission with Upadacitinib in two patients with anti-TNF-refractory macular edema associated with Beh\u00e7et's uveitis","volume":"32","author":"Tao","year":"2024","journal-title":"Ocul Immunol Inflamm"},{"issue":"4","key":"10.1016\/j.semarthrit.2026.153040_bib0029","doi-asserted-by":"crossref","DOI":"10.1002\/iid3.1242","article-title":"Coexistence of ankylosing spondylitis and Beh\u00e7et's disease: successful treatment with upadacitinib","volume":"12","author":"Kraev","year":"2024","journal-title":"Immun Inflamm Dis"},{"key":"10.1016\/j.semarthrit.2026.153040_bib0030","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1483993","article-title":"Case report: successful remission with upadacitinib in a young patient with anti-TNF-refractory intestinal Beh\u00e7et's disease","volume":"15","author":"Sha","year":"2024","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.semarthrit.2026.153040_bib0031","first-page":"e1","article-title":"Use of Upadacitinib in refractory Behcet's disease: case report and systematic literature review","volume":"24","author":"Patel","year":"2025","journal-title":"J Drugs Dermatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2026.153040_bib0032","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s11739-025-03874-x","article-title":"Targeting Janus kinase 1 in refractory Beh\u00e7et's disease: a case report on the clinical efficacy of Upadacitinib","volume":"20","author":"Ammoscato","year":"2025","journal-title":"Intern Emerg Med"},{"issue":"4","key":"10.1016\/j.semarthrit.2026.153040_bib0033","doi-asserted-by":"crossref","DOI":"10.1111\/1756-185X.70231","article-title":"Case report: successful remission with Upadacitinib in Beh\u00e7et's syndrome following a history of PFAPA syndrome","volume":"28","author":"Oka","year":"2025","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.semarthrit.2026.153040_bib0034","article-title":"Upadacitinib for refractory Beh\u00e7et's disease with myelodysplastic syndrome and trisomy 8\/9: a case report and mechanistic insights","volume":"16","author":"Wang","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.semarthrit.2026.153040_bib0035","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-026-03778-x","article-title":"Upadacitinib for refractory Behcet's syndrome: a multi-centre, single-arm trial","author":"Li","year":"2026","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2026.153040_bib0036","article-title":"Successful upadacitinib treatment in anti-TNF-refractory intestinal Beh\u00e7et's disease: a case report and literature review","volume":"13","author":"Shi","year":"2026","journal-title":"Front Med"},{"key":"10.1016\/j.semarthrit.2026.153040_bib0037","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2026.1761519","article-title":"The IL-23\/IL-17 axis in Beh\u00e7et\u2019s syndrome pathogenesis: from immunological perspectives to therapeutic implications","volume":"17","author":"Naffaa","year":"2026","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.semarthrit.2026.153040_bib0038","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/cei.13664","article-title":"Neutrophil-mediated mechanisms of damage and in-vitro protective effect of colchicine in non-vascular Beh\u00e7et's syndrome","volume":"206","author":"Bettiol","year":"2021","journal-title":"Clin Exp Immunol"},{"issue":"12","key":"10.1016\/j.semarthrit.2026.153040_bib0039","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nrrheum.2015.147","article-title":"MHC-I-opathy'-unified concept for spondyloarthritis and Beh\u00e7et disease","volume":"11","author":"McGonagle","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.semarthrit.2026.153040_bib0040","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.clim.2016.09.014","article-title":"Role of the JAK\/STAT signaling pathway in regulation of innate immunity in neuroinflammatory diseases","volume":"189","author":"Yan","year":"2018","journal-title":"Clin Immunol"},{"issue":"1","key":"10.1016\/j.semarthrit.2026.153040_bib0041","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"10.1016\/j.semarthrit.2026.153040_bib0042","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3390\/cells8030285","article-title":"IL-6, IL-12, and IL-23 STAT-pathway genetic risk and responsiveness of lymphocytes in patients with multiple sclerosis","volume":"8","author":"von Essen","year":"2019","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.semarthrit.2026.153040_bib0043","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.3390\/biomedicines13061325","article-title":"JAK inhibitor and Crohn's disease","volume":"13","author":"Xu","year":"2025","journal-title":"Biomedicines"},{"issue":"Supplement_2","key":"10.1016\/j.semarthrit.2026.153040_bib0044","doi-asserted-by":"crossref","first-page":"S746","DOI":"10.1093\/ecco-jcc\/jjz186","article-title":"Efficacy of JAK inhibitors in Crohn's disease","volume":"14","author":"Rogler","year":"2020","journal-title":"J Crohns Colitis"},{"issue":"9","key":"10.1016\/j.semarthrit.2026.153040_bib0045","doi-asserted-by":"crossref","first-page":"8176","DOI":"10.3390\/ijms24098176","article-title":"Intestinal Behcet's disease: a review of the immune mechanism and present and potential biological agents","volume":"24","author":"He","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10.1016\/j.semarthrit.2026.153040_bib0046","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/s41584-024-01153-1","article-title":"JAK inhibitor selectivity: new opportunities, better drugs?","volume":"20","author":"Virtanen","year":"2024","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2026.153040_bib0047","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1136\/ard-2023-223850","article-title":"Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story","volume":"83","author":"Bonelli","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.semarthrit.2026.153040_bib0048","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/rheumatology\/kead448","article-title":"Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases","volume":"63","author":"Taylor","year":"2024","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.semarthrit.2026.153040_bib0049","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/s41584-022-00880-7","article-title":"Vascular Beh\u00e7et syndrome: from pathogenesis to treatment","volume":"19","author":"Bettiol","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.semarthrit.2026.153040_bib0050","article-title":"Risk of venous thromboembolism with Janus kinase inhibitors in inflammatory immune diseases: a systematic review and meta-analysis","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.semarthrit.2026.153040_bib0051","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2011.026","article-title":"Beh\u00e7et's syndrome and thrombosis","volume":"3","author":"Seyahi","year":"2011","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"10","key":"10.1016\/j.semarthrit.2026.153040_bib0052","first-page":"1799","article-title":"Assessing the efficacy of anticoagulation therapy in the treatment of vascular Beh\u00e7et's disease: a systematic review","volume":"43","author":"Omar","year":"2025","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"10.1016\/j.semarthrit.2026.153040_bib0053","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.3390\/ijms22052449","article-title":"Thromboembolic adverse drug reactions in Janus kinase (JAK) inhibitors: does the inhibitor specificity play a role?","volume":"22","author":"Kotyla","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.semarthrit.2026.153040_bib0054","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/00004836-200003000-00006","article-title":"Gastrointestinal manifestations of Behcet's disease","volume":"30","author":"Bayraktar","year":"2000","journal-title":"J Clin Gastroenterol"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017226001307?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017226001307?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T03:58:51Z","timestamp":1788753531000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017226001307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":54,"alternative-id":["S0049017226001307"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2026.153040","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of Janus kinase inhibitors in Beh\u00e7et\u2019s disease: A systematic literature review","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2026.153040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"153040"}}